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CCAAT/enhancer binding protein (C/EBP)
 
 
 
 is a myeloid-specific transcription factor that 
couples lineage commitment to terminal differentiation and cell cycle arrest, and is found 
mutated in 9% of patients who have acute myeloid leukemia (AML). We previously showed 
that mutations which dissociate the ability of C/EBP
 
 
 
 to block cell cycle progression 
through E2F inhibition from its function as a transcriptional activator impair the in vivo 
development of the neutrophil granulocyte and adipose lineages. We now show that such 
mutations increase the capacity of bone marrow (BM) myeloid progenitors to proliferate, 
and predispose mice to a granulocytic myeloproliferative disorder and transformation of the 
myeloid compartment of the BM. Both of these phenotypes were transplantable into lethally 
irradiated recipients. BM transformation was characterized by a block in granulocyte 
differentiation, accumulation of myeloblasts and promyelocytes, and expansion of myeloid 
progenitor populations—all characteristics of AML. Circulating myeloblasts and hepatic 
leukocyte infiltration were observed, but thrombocytopenia, anemia, and elevated leukocyte 
count—normally associated with AML—were absent. These results show that disrupting the 
cell cycle regulatory function of C/EBP
 
 
 
 is sufficient to initiate AML-like transformation of 
the granulocytic lineage, but only partially the peripheral pathology of AML.
 
Transcription factors have emerged as key regu-
lators of lineage determination and differentiation
during hematopoiesis, and can be divided
roughly into two categories: factors generally
required for definitive hematopoiesis, includ-
ing AML1/Runx1 and GATA-2, and those
involved more specifically in the differentia-
tion of a single or a few related lineages, such
as PU.1, CCAAT/enhancer binding protein
(C/EBP)
 
 
 
, GATA-1, GATA-3, friend of
GATA, Pax5, and E2A (for review see reference
1). These cell type–restricted transcription factors
are of particular interest to the study of acute
leukemias, which are characterized most often
by a block in differentiation along a particular
lineage, because molecules that are important
for normal differentiation are good candidate
targets for the genetic abnormalities that are asso-
ciated  with leukemogenesis. Recent reports
have supported this view because acquired
mutations in the genes encoding C/EBP
 
 
 
,
PU.1, and GATA-1 have been found in patients
who have leukemias that affect the cell types
for which these proteins are important for differ-
entiation: C/EBP
 
 
 
 is essential for granulopoiesis
in vivo (2), and several studies have found
C/EBP
 
 
 
 mutations in patients who have
acute myeloid leukemia (AML), mostly of the
granulocytic M1 and M2 subtypes (3–7). PU.1
is essential for the development of the mono-
cyte/macrophage lineage (8, 9), and is found
mutated in the monocytic M4 and M5 AML
subtypes, as well as in undifferentiated M0
AML (10); the latter may reflect a role for
PU.1 in early myeloid lineage commitment
(11). Finally, GATA-1, a factor important for
erythroid and thrombocytic differentiation, has
been found mutated in the thrombocytic M7
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subtype associated with trisomy 21 (12). In the case of PU.1
and C/EBP
 
 
 
, the relevance of interference with their func-
tion is supported by the finding that translocation products
(BCR-ABL, AML-ETO) found in patients who have leuke-
mia inhibit their expression or activity by several diverse
mechanisms, including direct protein-protein interaction,
transcriptional down-regulation, and translational repression
(13–17), For PU.1, this concept is supported further by the
recent finding that mice carrying mutations in the PU.1 reg-
ulatory sequences that significantly lower its expression de-
velop AML (18).
In addition to being a key regulator of normal neutrophil
granulocyte, eosinophil, and adipocyte development (2, 19),
C/EBP
 
 
 
 is a potent suppressor of cell proliferation. Several
mechanisms for C/EBP
 
 
 
 cell cycle control have been pro-
posed, including induction of p21cdki (20), interaction with
cdk2/4 (21), and repression of the E2F complex of cell cycle
regulatory transcription factors (22–24). Analysis of the
C/EBP
 
 
 
 functions necessary for induction of granulopoiesis
in the 32D and K562 myeloid progenitor cell lines and of ad-
ipogenesis in NIH3T3 cells showed a requirement for
C/EBP
 
 
 
 domains mediating E2F repression, whereas the
cdk2/4 interacting region was dispensable (23, 25, 26). Con-
trol of E2F activity is an important step in terminal differenti-
ation of granulocytes and adipocytes, because ectopic E2F-1
expression is sufficient to block terminal differentiation of these
cell types in vitro (23, 27). C/EBP
 
 
 
 represses the E2F com-
plex via direct protein–protein interaction (23, 24, 26). Con-
sistent with this, neutrophil granulopoiesis and adipogenesis
are impaired severely in vivo by point mutations in the C/EBP
 
 
 
basic region that disrupt C/EBP
 
 
 
–E2F interaction, and
thereby, E2F repression by C/EBP
 
 
 
 (23). In addition to
these non-DNA binding residues in the C/EBP
 
 
 
 basic re-
gion, the NH
 
2
 
-terminal part of the C/EBP
 
 
 
 transactivation
domain is required for C/EBP
 
 
 
 to repress E2F activity (23,
24, 26). Normally, the C/EBP
 
 
 
 mRNA is translated into
two polypeptides: a full-length 42-kD form (p42) and a
shorter 30-kD form (p30; reference 28). The most common
type of C/EBP
 
 
 
 mutation in patients who have AML specif-
ically blocks the translation of p42 and leads to p30 overex-
pression (3–7; for review see reference 29). Because p30 is
derived from an internal AUG codon it lacks the NH
 
2
 
-termi-
nal part of the C/EBP
 
 
 
 transactivation domain, and there-
fore, cannot repress E2F activity (24). Together, these obser-
vations suggest that loss of C/EBP
 
 
 
-mediated E2F repression
contributes to the development of AML.
To address this question genetically we examined mice
homozygous for a C/EBP
 
 
 
 knock-in mutation that impairs
E2F repression. We found that myeloid progenitors from
these mice have increased replating efficiency, and that with
high frequency they develop a granulocytic myeloprolifera-
tive disorder or undergo transformation of the myeloid com-
partment of the BM with a block in granulocyte differentia-
tion. The myeloproliferative disorder and the transformed
phenotype were transplantable into lethally irradiated recipi-
ents. BM transformation was accompanied by expansion of
the myeloid progenitor compartment, as well as the c-Kit
 
 
 
and Lin
 
 
 
Sca-1
 
 
 
c-Kit
 
 
 
 populations, but no detectable in-
crease in long-term repopulating cells. These results provide
direct genetic evidence that C/EBP
 
 
 
-mediated E2F repres-
sion is important for controlling progenitor proliferation in
the myeloid compartment in vivo; that its impairment pro-
motes transformation of the granulocytic compartment of
the BM; and therefore, that mutations in a lineage-specific
transcription factor may contribute directly to AML.
 
RESULTS
BM transformation and myeloproliferation 
in C/EBP
 
 
 
 mutant mice
 
We previously described mouse strains containing point mu-
tations in the basic region of the C/EBP
 
 
 
 protein (basic re-
gion mutants [BRM] 1, 2, and 5; reference 23). Of these,
BRM2 and BRM5 preserve C/EBP
 
 
 
 DNA binding and
promoter activation, but prevent association of C/EBP
 
 
 
with the E2F complex, and thereby, impair C/EBP
 
 
 
-medi-
ated E2F repression; BRM1 is unaffected in this respect (23,
26). In young adult mice (8 wk) homozygous for the BRM2
(“BRM2 mice”) or BRM5 allele, Mac-1
 
 
 
/Gr-1
 
 
 
 granulo-
Figure 1. Myeloproliferative disease in BRM2 mice. (A) Splenomegaly in 
BRM2 mouse compared with WT mouse, both 36 wk of age. (B, C) May-
Grünwald-Giemsa–stained cytospin preparations of cells from WT (B) and 
BRM2 (C) spleens shown in (A). Note the prevalence of neutrophil granu-
locytes (cells with condensed, doughnut-shaped nuclei) in the BRM2 
spleen. Original magnification, 100. Flow cytometric analysis of erythroid 
and myeloid cells in BM from the above WT (D, E) and BRM2 (G, H) mice. 
Cells were triple-stained with Mac–1-FITC, TER119-PE, and Gr-1-APC or 
isotype-matched control antibodies, and analyzed on a FACSCalibur flow 
cytometer. The percentage of Mac-1 /Gr-1  (granulocytic) and TER119  
(erythroid) cells in each sample is indicated. Cytospins (original magnifica-
tion, 100) of BM samples confirmed the abundance of neutrophil granulo-
cytes in the BRM2 BM (I) compared with the WT control (F). 
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cytic cells were few or absent in the BM and peripheral
blood. However, examination of older BRM2 mice (36 wk)
revealed frequent splenomegaly (Fig. 1 A), accompanied by a
strong increase in spleen granulocytes (Fig. 1, B and C). The
number of Mac-1
 
 
 
/Gr-1
 
 
 
 BM cells was increased in these
mice; in the most severely affected animals the BM consisted
almost entirely of granulocytic cells (
 
 
 
85%; Fig. 1, D and F
vs. Fig. 1, G and I). Consequently, the number of TER119
 
 
 
erythroid cells was reduced substantially in the BM of these
animals (Fig. 1 E vs. Fig. 1 H). Further analysis confirmed
this phenotype and showed that it occurred in a virtually
identical manner in BRM5 mice, whereas BRM1 or control
knock-in mice were unaffected (unpublished data). At this
point we chose the BRM2 line for further analysis.
When compared with littermate control mice, BRM2
mice displayed no detectable excess mortality (unpublished
data). Therefore, to evaluate the progression of hemato-
logic disorders we systematically analyzed the granulocytic
cells in BM and spleen cells from BRM2 mice of 8, 12, 24,
36, 60, and 75 wk of age. This analysis revealed three dis-
tinct phenotypes (data summarized in Fig. 2). The pheno-
type originally observed in young adult BRM2 mice (i.e.,
few or no BM granulocytes [
 
 
 
12% Mac-1
 
 
 
/Gr-1
 
 
 
 BM
cells] and a relative increase in BM erythroid cells; refer-
ence 23)—most likely due to the loss of granulocytic cell
types—was found in 6/6 BRM2 mice at 8 wk of age
(BRM2-A phenotype; an example is shown in Fig. 3 A);
still was observed in a high proportion of mice at 12 wk of
age (4/10 mice or 40%); but was more rare in mice of 24
wk or older (5/29 mice or 17%). BRM2-A mice had rela-
tively normal levels of c-Kit
 
 
 
 BM cells (
 
 
 
6%), although
overall, a slight elevation relative to the control group was
observed (Fig. 2 B). Most likely this is attributable to the
loss of the granulocytic compartment which leads to a rela-
tive increase in progenitor levels.
Figure 2. Development of myeloproliferative disease. (A) Flow cyto-
metric analysis of BM from control ( / , BRM2/ ) and BRM2 (BRM2/
BRM2) mice at 8, 12, 24, 36, 60, and 75 wk of age, performed as in Fig. 1. 
For each mouse analyzed, a pair of columns shows the percentage of Mac-1 /
Gr-1  and TER119  cells. Mice in each genotype/age group are organized 
according to the number of Mac-1 /Gr-1  cells present (increasing left to 
right). The cut-offs used to define the BRM2 phenotypes are indicated 
(BRM2-A:  12% Mac-1 /Gr-1 ; BRM2-B:  55% Mac-1 /Gr-1  BM 
cells). These cut-off values differ from the mean value (38.2%; n   30) 
observed in control mice by more than two standard deviations (SD   7.1%), 
and were observed in the control group only once. The level of Ter119  
cells in BRM2-A mice and of Mac-1 /Gr-1  cells in BRM2-B mice were 
significantly greater than the levels observed in control mice (P   10 17 
and P   10 16, respectively). (B) Levels of c-Kit positive cells in BM from 
control mice (n   11), BRM2-A (n   4), BRM2-B (n   4), and BRM2-C 
(n   6) mice. **P   0.005; ***P   0.00005 compared with control mice. 
 /?,  /  and  /BRM2; A, BRM2-A; B, BRM2-B; C, BRM2-C. (C) Pheno-
typic progression of BRM2 mice.
Figure 3. Three distinct BRM2 phenotypes. Distinct FACS profiles 
showing TER119 (a panels) and Mac-1/Gr-1 (b panels) staining and May-
Grünwald-Giemsa–stained cytospins (c panels; original magnification, 
100) of BM cells from representative mice. The percentage of TER119  and 
Mac-1 /Gr-1  cells are indicated. 
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At 
 
 
 
12 wk of age, most mice contained significant levels
of Mac-1
 
 
 
/Gr-1
 
 
 
 cells. These could be divided into two
groups; the BRM2-B group (15/45 mice; 33%) contained
highly elevated (
 
 
 
55%) levels of BM Mac-1
 
 
 
/Gr-1
 
 
 
 cells
with the morphology of normally differentiated granulocytes
(Fig. 3 B). This group had levels of c-Kit
 
 
 
 BM cells that
were comparable to WT controls (
 
 
 
6% of nucleated BM
cells). The most severely affected BRM2-B animals (
 
 80%
Mac-1 /Gr-1  BM cells) displayed splenomegaly and ele-
vated levels of spleen granulocytes as described in Fig. 1. The
second group (BRM-2C; 10/45 mice; 22%) contained a
moderate to high proportion (20–65%) of Mac-1 /Gr-1 
BM cells that stained weakly for the Gr-1 antigen (Fig. 3 C).
Because Gr-1 is a marker for terminal granulocyte differenti-
ation, this suggested a differentiation block along this lin-
eage. Consistent with this, the morphology of BM myeloid
cells from BRM2-C mice was immature (elevated numbers
of myeloblasts and promyelocytes; Fig. 3 C, panel c). Finally,
the BRM2-C mice contained abnormally high (6–20%)
c-Kit–positive BM cells (Fig. 2 B). Two mice did not fit
this classification, but had normal levels (20–35%) of mor-
phologically normal Mac-1 /Gr-1  granulocytes and normal
c-Kit  levels; these most likely represent a transition state
between the BRM2-A and -B phenotypes. The proportion
of BRM2 mice with the three phenotypes progressed from
BRM2-A in young mice to  40% BRM2-C in mice  6
mo of age (Fig. 2 C); this suggested a progression from
BRM-2A toward BRM2-C, with BRM2-B as a possible in-
termediate phenotype. No hematopoietic disorder was ob-
served in any age- and litter-matched control WT or het-
erozygous mice (n   30).
To determine the differentiation profile of the granulo-
cytic compartment in mice with the three different BRM2
phenotypes, we performed differential counts on BM
cytospins (Fig. 4 A). This analysis confirmed that BRM2-A
mice had an early block in granulocyte differentiation, few
cells progressing beyond the myeloblast stage, and no accu-
mulation of immature myeloid cells (23). In the BRM2-B
phenotype, granulocyte differentiation seemed to be mor-
phologically normal, but levels of mature neutrophil granu-
locytes were abnormally high, consistent with the elevated
levels of Mac-1 /Gr-1  cells in the BM. In contrast, the
BRM2-C phenotype showed loss of granulocyte matura-
tion and accumulation of myeloblasts and early progenitors
(mostly promyelocytes) similarly to what is observed in hu-
Figure 4. Differentiation profile of granulocytes and hematologic 
parameters in BRM2 mice. (A) Differential counts on cytospins of BM 
from representative mice. The percentage of nucleated cells at different 
granulocytic maturation stages is shown. *A leukemic phenotype (M2 
AML;  20% myeloblasts [30]).  300 cells were counted per sample. 
(inset) Myeloid blast in peripheral blood smear from BRM2-C mouse (May-
Grünwald-Giemsa stain). (B–D) Leukocyte infiltration in the liver of BRM2-C 
mice. Hematoxylin-eosin–stained paraffin sections of WT control (B) and 
BRM2-C mice (C, D). Infiltrating leukocytes form blue clusters; immature 
myeloid cells (myeloblasts/promyelocytes) are indicated by arrows in (D). 
Original magnification, 40 (B, C) and 100 (D). (E–H) Control ( /? , /  and 
BRM2/ : n  11) and BRM2 mice (A, BRM2-A: n   4; B, BMR2-B: n   4; 
C, BRM2-C: n   6) of 60–75 wk of age were analyzed for peripheral blood 
levels of (E) platelets, (F) hemoglobin (HGB), (G) erythrocytes (RBC, red 
blood cells), and (H) leukocytes (WBC, white blood cells). Error bars indicate 
standard deviations. *P   0.05 compared with controls. (I) 10  g total BM 
RNA from mice with the indicated genotypes were subjected to sequential 
Northern blotting with probes specific for the G-CSF-R, GM-CSF-R , 
M-CSF-R, and 18S rRNA. White lines indicate that intervening lanes have 
been spliced out. (J) Receptor expression from (I) was quantified using a 
Fuji BAS2500 phosphorimager. Average expression levels and the percent-
age of Mac1 /Gr1  cells (36.5% in WT), are shown normalized to WT lev-
els for the three BRM2 subtypes.JEM VOL. 202, July 4, 2005 89
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man M2 AML (30). The transformed phenotype of the BM
of BRM2-C mice led us to examine whether these mice
displayed peripheral phenotypes associated with AML.
However, relatively few myeloid blasts (1–6% of nucleated
cells) were observed in peripheral blood smears from
BRM2-C mice (Fig. 4 A, inset and not depicted). Examina-
tion of peripheral hematopoietic organs revealed no in-
crease in immature myeloid cells in the spleens of BRM2-C
mice, but 2/10 mice had hematopoietic infiltrations that in-
cluded immature myeloid cells in the liver (Fig. 4, B–D).
Comparison of control and BRM2 mice of  1 yr of age did
not reveal thrombocytopenia (Fig. 4 E) or anemia (Fig. 4, F
and G) in the BRM2-C group, and BRM2-C white blood
cell counts were not significantly different from those of
control mice (Fig. 4 H); this was consistent with the low
levels of myeloid blasts observed in the peripheral blood of
BRM2-C mice. The lack of severe AML-associated periph-
eral phenotypes most likely explains why no increased mor-
tality of BRM2 mice was detected compared with WT or
heterozygous controls.
The defects in granulocyte differentiation may be attrib-
utable to deregulation of receptors for myeloid growth fac-
Figure 5. Maintenance and progression of BRM2 phenotypes 
during BM transplantation. Analysis of recipient BM, from mice trans-
planted with BM from mice displaying the BRM2-A (A), -B (B), and -C phe-
notypes (C), as well as control BM (D) (panels d-f). The parallel analysis of 
the donor BM is shown for comparison (panels a–c). Panels show staining 
for Mac-1 and Gr-1 (panels a, d, and g); for c-Kit and Mac-1 (panels b, e, 
and h); and cytospins stained with May-Grünwald-Giemsa (panels c, f, 
and i). In the case of BRM2-A and BRM2-B, examples are shown of mice in 
which phenotypic progression toward the BRM2-C phenotype was observed 
(panels g–i). In all surviving recipients  90% of hematopoietic cells were 
of donor origin.GRANULOCYTE LINEAGE TRANSFORMATION IN C/EBP  MUTANT MICE | Porse et al. 90
tors, such as G-, GM- and M-CSF-R, which contain func-
tionally important C/EBP  sites in their promoter (31).
Northern blot analysis of BM from WT and BRM2 mice
showed that granulocyte colony-stimulating factor receptor
(G-CSF-R), macrophage colony-stimulating factor receptor
(M-CSF-R), and GM-CSF-R  levels generally were pro-
portional to the number of granulocytic, and hence, mye-
loid cells present (Fig. 4, I and J). Therefore, it seems that
the BRM2 mutation does not decrease activation of these
promoters significantly. Consistent with this activation of a
G-CSF-R reporter by C/EBP  BRM2 in transient trans-
fection assays was the same as that seen with WT C/EBP 
(unpublished data).
In summary, mice homozygous for the C/EBP  BRM2
mutation, starting at 12 wk of age, progressed with high fre-
quency from a neutropenic state to a myeloproliferative dis-
order which affected the granulocyte lineage, or to a condi-
tion in which the myeloid compartment of the BM was
transformed with features of M2 AML, but in which periph-
eral involvement was relatively weak.
The BRM2 phenotypes are transplantable
The progression observed in BRM2 mice raised the ques-
tion of how these distinct phenotypes arise. In particular, the
possibility existed that the hyperproliferative BRM2-B phe-
notype was a reactive condition that was induced in response
to infection or inflammation. Therefore, BM from BRM2-
A, -B, and -C mice, as well as from  /  controls (all of the
CD45.2 allotype), was transplanted into lethally irradiated
C57BL/6-CD45.1/2 recipients (results summarized in Table
I). In all cases most of the recipients survived and these were
engrafted efficiently ( 90%). All three BRM2 phenotypes
were transplantable, in that most recipients displayed the
same BM phenotypes as their respective donors (Fig. 5). In a
few cases (3/13), transplantation with BRM2-A or -B BM
gave rise to mice that had progressed toward a BRM2-C
phenotype (e.g., Fig. 5, A and B, panels g–i). This argued
against a reactive or environmental origin of the BRM2
phenotypes, and indicated that they most likely differ as a re-
sult of accumulated genetic alterations; in particular, the ob-
served progression of BRM2-A and -B toward BRM2-C—
but not the opposite—was consistent with a genetically
driven, irreversible process.
C/EBP  mutations increase the proliferative capacity of 
myeloid progenitors
To determine the cellular mechanisms that underlie the ob-
served transformation of the granulocytic BM compartment,
we next investigated the levels and replating efficiency of
myeloid progenitors from BRM2 and control mice. BM
cells were plated in semi-solid medium to allow outgrowth
of all myeloid cell types, and the number of colonies was ob-
served. Colonies were harvested and cells were replated to
determine the proliferative ability of myeloid progenitors.
Representative data are shown in Fig. 6 A. Progenitors from
WT mice had the expected limited proliferative capacity, as
illustrated by the rapidly decreasing number of colonies ob-
Table I. Noncompetitive repopulation
Donor genotype/
phenotype
Recipient
survival
Recipient
phenotype
 /  7/7 normal
BRM2-A 5/7 4A, 1 progressed towards C
BRM2-B 8/10 6B, 2 progressed towards C
BRM2-C 3/4 3C
2   106 CD45.2 donor BM cells were injected into the tail vein of lethally irradiated 
CD45.1/2 C57BL/6 mice. Mice were analyzed 9–12 wk after transplantation. Donor 
contributions were  90%; all dead recipients died within 3 wk.
Figure 6. Myeloid progenitor levels and proliferation in BRM2 
mice. (A) Myeloid CFUs observed in successive replatings of BM from 
representative WT (n   4), BRM2-A (n   2), BRM2-B (n 2), and BRM2-C 
(n   2) mice. 5–20,000 cells were plated in methylcellulose-based semi-
solid medium allowing outgrowth of all myeloid colony types. The number 
of day 7 myeloid colonies obtained per 10,000 cells plated is shown for 
each of five successive platings. (B) Myeloid colony types obtained from 
BM of WT (n   8), BRM2-A (n   4), BRM2-B (n   5), and BRM2-C (n   3) 
mice. 5–20,000 BM cells were plated as in (A) and the number of multipotent 
(CFU-GEMM), committed myeloid (CFU-GM), and committed erythroid 
(BFU-E) progenitors were scored after 10–12 d. Colony numbers obtained 
per 10,000 cells are shown. Error bars indicate standard deviations. 
*P   0.05 for BRM2-C mice compared with control mice and nontrans-
formed BRM2-A and -B mice.JEM VOL. 202, July 4, 2005 91
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tained upon successive replatings. BRM2-A and -B mice
contained a number of colony-forming progenitors similar
to that found in WT BM, but their replicative potential was
significantly greater; they continued to proliferate at the
fourth replating (and in most cases well beyond; unpublished
data). BRM2-C mice consistently contained significantly el-
evated levels of progenitors (as measured by the initial plat-
ing efficiency), also with high self-renewal capacity. The
observation that progenitors from mice of all BRM2
phenotypes displayed increased replicative potential in vitro
indicates that C/EBP  directly controls the ability of mye-
loid progenitors to expand. However, this seemed to lead to
an in vivo expansion of the progenitor compartment only in
mice with BM transformation. To determine the identity of
the myeloid progenitors present in the different geno-/phe-
notypes, colony assays were performed (Fig. 6 B); this showed
that in BRM2-A and -B BM, multipotent (CFU-granulo-
cyte/erythrocyte/macrophage/megakaryocyte [GEMM]) and
committed (CFU-granulocyte/macrophage [GM], burst-form-
ing units–erythrocyte [BFU-E]) progenitors were present in
numbers that were comparable to those found in WT mice.
In contrast, BRM2-C mice contained significantly elevated
Figure 7. HSC and progenitor compartments in BRM2 mice. Flow 
cytometric determination of BM progenitors. Progenitor analysis of BM 
cells was performed as described previously (52). The percentage of nucle-
ated BM cells with the immunophenotype of HSCs, CMPs, GMPs, and 
megakaryocyte-erythroid progenitors (MEP) is indicated. The diagram in 
the (A) panel shows the phenotyping strategy. Typical examples of analy-
ses of WT (B), BRM2-A (C), BRM2-B (D), and BRM2-C (E) mice are shown.GRANULOCYTE LINEAGE TRANSFORMATION IN C/EBP  MUTANT MICE | Porse et al. 92
levels of committed and multipotent progenitors; this sug-
gested that an expansion of a very early myeloid progenitor
population had occurred in these mice.
Early myeloid progenitors and Lin Sca-1 c-Kit  cells are 
expanded in BM from transformed BRM2 mice
The above results suggested that mutation of C/EBP , in
addition to its well-characterized effects on granulocyte dif-
ferentiation, affected an immature, proliferative compart-
ment in the BM. To substantiate this finding we used the
immunophenotyping protocol developed by Weissman and
colleagues (32, 33). Typical examples of such analyses, per-
formed on control and BRM2 mice, are shown in Fig. 7; re-
sults are summarized in Fig. 8 A. These experiments revealed
that bipotent granulocyte/macrophage progenitors (GMP),
multipotent common myeloid progenitors (CMPs), and
phenotypically defined (Lin Sca-1 c-Kit ) hematopoietic
stem cells (HSCs) were increased significantly in BRM2-C
mice compared with nontransformed BRM2-A/B mice. In
particular, the HSC population was increased by an average
of 10-fold compared with nontransformed BRM2 mice. Fi-
nally, we observed an increase in the proportion of c-Kit 
cells in the Lin Sca-1 IL-7R  progenitor population in all
BRM2 mice, regardless of their BM phenotype (Fig. 7, B–E,
d panel; and not depicted).
The HSC population as defined above are not only re-
populating stem cells, but are a mixture of repopulating stem
cells and short-term pluripotent myeloid/lymphoid progeni-
tors (sometimes referred to as “short-term” HSCs). To ad-
dress the nature of the expanded Lin Sca-1 c-Kit  com-
partment in BRM2-C mice, we performed competitive
repopulation assays in which WT CD45.1 competitor BM
cells were cotransplanted with BRM2-B, BRM2-C, or WT
control BM cells into irradiated CD45.1/2 recipients at a 10:1
ratio. These assays showed a decreased hematopoietic con-
tribution of BRM2 BM compared with WT BM, with no
difference seen between the BRM2-B and -C phenotypes
(Fig. 8 B). This indicated that repopulating activity was not
greater in the transformed BRM2-C BM, and that the in-
creased proportion of Lin Sca-1 c-Kit  cells most likely re-
flects an increase in multi-/pluripotent progenitors, rather
than repopulating cells.
DISCUSSION
The results presented here allow us to reach three main con-
clusions. First, mutations in C/EBP  that impair C/EBP –
E2F association have the capacity to induce transformation
of the myeloid compartment of the BM. This phenotype
was seen only in mice homozygous for the mutations—indi-
cating their recessive nature—and was consistent with loss-
of-function as their main effect. Second, our data indicate
that the cellular mechanism involves an increased replating
efficiency of myeloid progenitors, correlating with c-Kit up-
regulation in the progenitor-containing Lin Sca-1 IL-7R 
BM population. This indicates a role for C/EBP -mediated
E2F repression in controlling the proliferative capacity of
early myeloid progenitors. Finally, although BM transforma-
tion did not lead to an increase in long-term repopulat-
ing cells, it was associated with expansion of the c-Kit 
and Lin Sca-1 c-Kit  populations as well as CMP/CFU-
GEMM and GMP/CFU-GM progenitors; this indicated
that the target for BM transformation is an early multipotent
progenitor/stem cell population. These results provide ge-
netic evidence that targeting a myeloid lineage–specific tran-
scription factor, essential for normal granulocyte differentia-
Figure 8. HSC and progenitor compartments are expanded in 
BRM2-C mice. (A) Summary of flow cytometric determination of BM 
progenitors from WT (n   8), BRM2-A (n   3), BRM2-B (n   4), and 
BRM2-C (n   4) mice, determined as in Fig. 6. The average percentage of 
nucleated BM cells with the immunophenotype of HSC, common lymphoid 
progenitor cells (CLP), CMP, GMP, and megakaryocyte-erythroid progeni-
tors (MEP) is shown. Error bars indicate standard deviations. *P   0.05 for 
BRM2-C mice compared with nonleukemic BRM2-A and -B mice. **P   0.05 
for WT mice compared with BRM2-A/B mice. (B) Competitive repopulation 
of irradiated recipients using 200,000 WT CD45.1 competitor BM cells and 
20,000 CD45.2 BM cells from control mice (WT) or mice with the BRM2-B 
and -C phenotypes. Standard deviations are indicated by error bars. There 
was no difference between repopulation using BRM2-B or -C BM; overall, 
the level of repopulation observed with BRM2 donors was significantly 
less (*P   0.05) than that seen with WT controls, which repopulated with 
the same efficiency as the CD45.1 competitor cells.JEM VOL. 202, July 4, 2005 93
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tion, disrupts the normal regulation of progenitor cell
proliferation/differentiation and directly contributes to trans-
formation of the myeloid compartment of the BM, one of
the key features of AML.
C/EBP  mutation is sufficient to initiate BM transformation
Definitive evidence that gain or loss of function of a particu-
lar protein is important for tumor development only can be
obtained by direct in vivo mutagenesis. The present data,
showing that C/EBP  mutation by itself is sufficient to ini-
tiate the development of granulocytic myeloproliferative dis-
ease and an M2 AML-like BM transformation, provide
genetic evidence to support the role of C/EBP  as a myeloid-
specific tumor suppressor. Thus, our observations strongly
support the etiological relevance of cebpa mutations in pa-
tients who have AML, and inhibition of C/EBP  function
by translocation products found in myeloid leukemias. Pre-
viously, induction of AML-like disease in vivo by expression
of PML-RAR  or BCR-ABL transgenes (34–36), by ec-
topic Bcl-2 expression combined with the absence of Fas
signaling (37), and by ectopic AML-ETO expression in con-
junction with N-ethyl-N -nitrosourea mutagenesis (38, 39)
has been observed. However, the precise mechanisms of ac-
tion of translocation-derived oncoproteins remain unclear,
not least because each transgenically expressed oncoprotein
generally affects several cellular targets, in the case of AML-
ETO and BCR-ABL including C/EBP . In the present
study the C/EBP  BRM2 specifically targets the ability of
C/EBP  to repress E2F activity and identifies a specific cel-
lular pathway, the deregulation of which leads to BM trans-
formation. Because a common cebpa mutation in AML in-
volves loss of expression of C/EBP  p42 and overexpression
of the short p30 form of C/EBP  (4) which is incapable of
repressing E2F activity (24), this indicates strongly that E2F
repression is a critical feature of C/EBP  tumor suppressor
function. Although the BRM2 knock-in allele produces the
p42 and p30 isoforms at their normal ratio (23), we recently
observed that mice in which C/EBP  p42 (but not p30)
translation has been ablated and leads to a molecularly dis-
tinct but functionally similar loss of E2F repression, undergo
BM transformation in a manner similar to that described
here for BRM2 mice (M. Schuster, B. Porse, D. Tenen, and
C. Nerlov, unpublished data); this is consistent with the
above notion.
Control of myeloid progenitor proliferation by C/EBP 
We find that homozygosity for the C/EBP  BRM2 allele
increases the proliferative capacity of BM myeloid progeni-
tor cells in vitro. Although C/EBP  mRNA expression has
been observed in CMPs and GMPs (32), the function of
C/EBP  in these cell types has remained unclear. Our results
indicate that in addition to its role in promoting neutrophil
and eosinophil granulopoiesis (2, 40, 41), C/EBP  plays a
direct role in the control of early myeloid progenitor (CMP/
GMP) proliferation versus differentiation, and correlates
with up-regulation of c-Kit in the CMP/GMP-containing
Lin Sca-1 IL-7R  compartment. Our results further sug-
gest that loss of this control mechanism contributes to early
progenitor expansion during BM transformation. Two re-
cent reports have shown that the CMP to GMP transition is
impaired severely in this complete absence of C/EBP , and
this was associated with increased proliferative capacity of
myeloid progenitors (42, 43). In neither study was overt
granulocytic AML observed to develop from C/EBP -defi-
cient cells, most likely because C/EBP  is required for gran-
ulocyte lineage commitment, without which granulocyte-
type AML cannot occur (for discussion see reference 29).
Instead, accumulation of blasts in the BM was observed with
virtually no granulocytic maturation (42). We also see in-
creased progenitor proliferation and accumulation of imma-
ture myeloid BM cells without development of overt AML
in BRM2-C mice. However, formation of GMPs is not im-
paired in BRM2 mice, and some maturation along the gran-
ulocytic lineage is seen in transformed BRM2-C mice.
Therefore, the BM transformation that is caused by the
BRM2 is likely to have a molecular basis distinct from the
AML-like BM phenotype that was observed by Zhang and
co-workers (42), which seems to be due to an early block in
myeloid lineage commitment. This also is supported by the
delayed development of BM transformation in BRM2 mice
compared with the acute differentiation block seen by com-
plete deletion of C/EBP , which suggests the requirement
of additional mutations only in the case of BRM2 mice.
Although BRM2 impairs the ability of C/EBP  to re-
press E2F activity (23, 26) it was proposed instead that this
mutation reduces C/EBP  DNA binding capacity which
contributes to its inability to arrest cell proliferation (44).
However, this proposal is not consistent with the inability of
other investigators, as well as ourselves, to detect any loss of
C/EBP  transactivation of or binding to the G-CSF-R pro-
moter, either in vivo or in tissue culture experiments upon
introduction of this mutation (23, 25), nor does it explain the
observation that C/EBP  alleles with complete loss of DNA
binding are less defective in arresting myeloid cell cycle pro-
gression than the C/EBP  BRM2 allele (25). Granulocytes
from BRM2 mice express the G-CSF-R mRNA—a geneti-
cally defined C/EBP  target gene (2)—at levels similar to
those seen in WT granulocytes. Therefore, although we can-
not rule out formally that interactions with factors other than
E2F are impaired by BRM2, the available evidence indicates
loss of E2F interaction as the most likely basis for the pheno-
types observed. This is supported by studies in the K562 cell
line: here C/EBP  BRM2 is incapable of down-regulating
c-myc transcription via an E2F binding site in the c-myc pro-
moter (24, 26), showing that the BRM2 deregulates E2F in
differentiating granulocytes in vitro. This deregulation of the
E2F-Myc axis is the likely cause of the initial loss of granulo-
cytic cells (for discussion see reference 23). Current efforts are
directed at the identification of promoters that are deregu-
lated by C/EBP  BRM2 in vivo. Although the increasedGRANULOCYTE LINEAGE TRANSFORMATION IN C/EBP  MUTANT MICE | Porse et al. 94
self-renewal capacity correlated with an increase in the pro-
portion of Lin Sca-1 IL-7R  cells that were c-Kit positive,
it is not clear whether deregulation of c-Kit expression con-
tributes to, or merely reflects, this phenomenon. Although a
role for c-Kit in M2 AML is supported by the occurrence of
activating mutations in the c-kit gene in this leukemic subtype
(45) and c-Kit overexpression in BM cells of patients who
have AML (46), further analysis of the regulation of c-Kit ex-
pression by C/EBP  controlled pathways will be required to
determine the functional relevance of elevated levels of
c-Kit–expressing cells in the BRM2 mice.
Involvement of the stem cell compartment in 
BM transformation
BM transformation was observed in  22% of the BRM2
mice of 12 wk of age or older. The incomplete penetrance
and delayed occurrence indicates that BM transformation re-
quires additional genetic events. Although the nature of such
events is not clear, the consistent increase of bipotent (GMP/
CFU-GM), multipotent (CMP/CFU-GEMM), and pluripo-
tent (Lin Sca-1 c-Kit ) cells in transformed BM indicates
that the target cell resides very early in the hematopoietic dif-
ferentiation hierarchy. Although the AML-like BRM2-C
phenotype is transplantable, we do not find that the long-term
repopulating activity is increased in transformed BM relative
to the preleukemic state. Therefore, the most likely explana-
tion seems to be that the number of stem cells is not increased
in the leukemic mice, but that a subset of these, or of early
Lin Sca-1 c-Kit  progenitor cells, has undergone secondary
mutations that generate transplantable leukemic stem cells.
This results in production of elevated levels of multipotent
and myeloid-restricted progenitors—which fail to mature
along the granulocyte lineage—and in the transformed BM
phenotype. This is in line with earlier transplantation studies
that identified the “AML stem cell” from all tested human
acute leukemic subtypes as having a phenotype similar to the
HSC (CD34  CD38 ), and thereby, identified AML as a
disease residing in the stem cell compartment (47–49). Thus,
BRM-2 mutant mice may prove to be a valuable system for
the identification of transforming stem cell mutations in AML.
The observation that BRM2 HSCs have decreased competi-
tive repopulating activity compared with WT HSCs contrasts
with the observation that HSCs in which C/EBP  has been
deleted display increased competitive repopulation activity
(42). This indicates that the effect of the BRM2 mutation in
HSCs is distinct from complete loss of function, and that the
positive effect of C/EBP  deletion on HSC function may not
be related to C/EBP  cell cycle control, but rather to effects
on gene expression. This is consistent with the increased Bmi-1
expression that is seen in HSCs that lack C/EBP  (42).
The BRM2 mice undergo phenotypic progression, from
the BRM2-A phenotype (in mice  2 mo) toward BRM2-C
(which is the most prevalent phenotype in mice  6 mo).
These phenotypes are stable during transplantation which
suggests that the progression is due to accumulation of sec-
ondary mutations, rather than proliferative syndromes that
are induced by stromal defects, infection, or inflammation.
The observation that a proportion of mice that was trans-
planted with BRM2-A or -B BM progressed toward a
BRM2-C phenotype is consistent with this notion, and in-
dicates that the myeloproliferative state can serve as an inter-
mediate step in BM transformation. A preleukemic phase
with elevated BM neutrophil levels is seen in mice homozy-
gous for a PU.1 knockdown allele before progression to
overt AML (18). PU.1 and C/EBP  antagonize each other
during the granulocyte-macrophage lineage decision, possi-
bly by displacement of c-Jun—a PU.1 coactivator—by
C/EBP  (50, 51). However, the above observations suggest
that PU.1 and C/EBP  contribute to control of neutrophil
proliferation in vivo. The observed deregulation could in-
volve c-Myc overexpression, because c-Myc is up-regulated
in a significant proportion of PU.1 knockdown mice, possi-
bly through chromosomal amplification (18), and is re-
pressed by C/EBP  via E2F sites in the c-myc promoter
(24). However, it also is possible that if PU.1 levels are low it
may fail to sequester c-Jun, which could inhibit C/EBP 
(52). The individual contributions of these pathways to
granulocyte hyperproliferation remain to be determined.
In summary, we have found that loss of C/EBP -medi-
ated E2F repression results in deregulation of progenitor pro-
liferation in the myeloid compartment, and predisposes to the
development of transplantable myeloproliferative disorders of
the granulocytic lineage, including BM transformation with
features of M2 AML and in vivo expansion of multi- and bi-
potent myeloid progenitors, and the Lin Sca-1 c-Kit  com-
partment. Thus, our results provide a molecular link between
the clinically observed mutations in the cebpa gene in patients
who have AML and the finding that transplantation of AML
requires the early progenitor/stem cell compartment; this indi-
cates that C/EBP  mutant mice will prove to be a valuable
tool in studying the role of the stem cell compartment in AML
development. More generally, our results support the idea that
mutations in lineage-specific transcription factors play a direct
role in myeloid leukemogenesis. This notion is consistent with
the recent observation that reduced expression of PU.1 leads
to AML (18); it will be relevant to examine mice containing
appropriate PU.1 and GATA-1 knock-in mutations.
MATERIALS AND METHODS
Mouse strains. BRM2 mice were maintained on a mixed C57BL/6-129/
Ola background and genotyped as described previously (23). Mice with the
desired genotypes were maintained under specific pathogen-free conditions
for 8–75 wk before analysis. C57BL/6-CD45.1 or C57BL/6-CD45.2 mice
were bred at B & S. Animal care was in accordance with the institutional
guidelines of the Universities of Lund and Copenhagen, as well as Danish
and Swedish National guidelines.
Transplantation assays. BM transplants were performed essentially as de-
scribed (53). For simple transplantation (noncompetitive repopulation), le-
thally irradiated C57BL/6-CD45.1/2 recipients were injected into the tail
vein with 2   106 CD45.2 BM cells from WT donors or donors displaying
each of the three BRM2 phenotypes. The BM phenotype of the recipientsJEM VOL. 202, July 4, 2005 95
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was analyzed 9–12 wk after transplantation. For competitive repopulation
assays, CD45.1/2 recipients received 2   105 C57BL/6-CD45.1 competi-
tor cells and 2   104 CD45.2 test BM cells from BRM2 mice or their WT
controls. Relative engraftment of the CD45.2 cells was measured by flow
cytometry of peripheral blood leukocytes 8 wk after transplant. Although
donor cells were of a mixed C57BL/6-129/Ola background, this did not
affect detectably their ability to function in competitive repopulation against
C57BL/6 cells in C57BL/6 recipients, as observed previously (54).
Histology and peripheral blood analysis. BM cells were harvested as
described previously (23). Spleen cells were dissociated through a fine-gauge
needle in medium containing DMEM   10% FCS   20 mM Hepes-
KOH. Peripheral blood was used directly for blood smears. Methanol-fixed
cytospins and smears were stained with May-Grünwald-Giemsa. For differ-
ential counts,  300 cells from BM cytospins were counted for each sample.
Blood samples were examined on a KX21 automated hematology analyzer
(TOA Medical Electronics Co.). For histologic analysis, formalin-fixed (4%
paraformaldehyde) tissues were paraffin embedded, sectioned at 4  m, and
stained with hematoxylin-eosin.
Flow-cytometry and progenitor phenotyping. Flow cytometry was
performed by staining with anti–Mac-1-FITC, anti–TER119-PE, anti–
Gr-1-APC, anti–c-Kit-APC, or the corresponding isotype control antibod-
ies (BD Biociences) and analysis on a FACSCalibur flow cytometer (Becton
Dickinson). Progenitor analysis of BM cells was performed using antibodies
against lineage markers (B220, CD3, Mac-1, Gr-1, TER119, CD4, CD5,
CD8), c-Kit, Sca-1, IL-7R, Fc RII/III, and CD34 to define common mye-
loid progenitor cells (CMP; Lin Sca-1 IL7R c-Kit CD34 Fc RII/IIIlo),
GMP cells (Lin Sca-1 IL-7R c-Kit CD34 Fc RII/IIIhi), and megakaryo-
cyte-erythroid progenitors (Lin Sca-1 IL-7R c-Kit  CD34 Fc RII/IIIlo);
and with antibodies against lineage markers, c-Kit, Sca-1, and IL-7R to
define HSCs (Lin Sca-1 c-Kit ) and common lymphoid progenitor cells
(Lin IL-7R Sca-1loc-kitlo) as described previously (32, 33, 55). For analysis
of BM transplanted mice, peripheral blood leukocytes were stained with
anti–CD45.2-FITC and anti–CD45.1-PE to identify donor-derived cells.
Staining with anti-CD4, anti-CD8, anti-B220 (all PE-Cy5 conjugated),
anti-B220, and anti–Mac-1 (both allophycocyanin conjugated) was used to
distinguish T lymphocytes, B lymphocytes, and myeloid cells.
Colony assays and serial replating experiments. For the analysis of
colony-forming potential, BM cells (5,000–20,000 cells/35-mm dish) were
seeded in methylcellulose-based medium (M3434, StemCell Technologies
Inc.) supplied with erythropoietin, IL-3, IL-6, and stem cell factor. After
10–12 d in culture, the colonies were scored as CFU-GM, BFU-E, or
CFU-GEMM. In the serial replating experiments, a similar number of BM
cells was seeded in M3434 medium, cultured for 7 d, and the number of
colonies was counted. The cells were harvested, washed with PBS, diluted,
and replated in fresh M3434 medium and cultured for an additional 7 d.
This procedure was repeated for 5 wk.
Northern blotting. Total RNA was isolated from BM cells and Northern
blotting was performed as described (23) using cDNA probes for the
G-CSF-R, M-CSF-R, and GM-CSF-R  (18). An 18S rRNA probe (5 -
GTGCGTACTTAGACATGCATG-3 ) was used as a loading control.
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